A New Stage in Annals of Hepatology
Journal Title: Annals of Hepatology - Year 2018, Vol 17, Issue 3
Abstract
-<br/><br/>
Authors and Affiliations
Arturo Panduro, Claudio Tiribelli, Norberto C. Chávez-Tapia, Misael Uribe
Keywords
Related Articles
- EP ID EP345325
- DOI 10.5604/01.3001.0011.7377
- Views 119
- Downloads 0
Probiotics in non-alcoholic fatty liver disease: which and when
Non-alcoholic fatty liver disease (NAFLD) is a common and serious disease. Literature reports the central role of the gut-liver axis in the pathogenesis of NAFLD, and recently suggests that the microbiota is a casual fac...
Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study
[sup][/sup] Introduction and aim. Hyponatremia is common in patients with decompensated cirrhosis and is associated with increased mortality. Tolvaptan, a vasopressor V2 receptor antagonist, can increase free water excre...
Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant biliary obstruction
Ursodeoxycholic acid (UDCA) is the first choice medication for most cholestatic hepatopathies, due to its capability to counteract inflammation and bile-acid-induced liver damage, two common features in cholestasis. How...
Non-alcoholic fatty liver disease and the metabolic syndrome in an urban hospital serving an African community
Background. Liver disease continues to be a major cause of morbidity and mortality in sub-Saharan Africa, including Nigeria, due to the high endemicity of viral hepatitis B. However non-alcoholic fatty liver disease may...
Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study
[b]Background[/b]. Probiotics have profound effect on nonalcoholic steatohepatitis (NASH) in animal models. We aimed to test the hypothesis that probiotics treatment was superior to usual care in reducing liver fat in NA...